Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.
Published in Hawai i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health
Recent efforts directed at potential litigation in Hawai i have resulted in a renewed interest for genetic screening for cytochrome P450 2C19 (CYP2C19) polymorphisms in patients treated with clopidogrel. Clopidogrel is an antiplatelet agent, frequently used in combination with aspirin, for the prevention of thrombotic complications with acute coron...
